COMPLEX SCIENCE, CLEAR DIRECTION
INTEGRATED SCIENTIFIC AND REGULATORY STRATEGY FOR COMPLEX DRUG DEVELOPMENT PROGRAMS
DAWN SCIENTIFIC
DawnScientific is an integrated drug development practice led by Melissa Dawn, Principal Scientist and Managing Director. The practice helps teams shape development strategy and navigate complex scientific and regulatory challenges, from early program design through high-scrutiny technical review and regulatory authority engagement.
END-TO-END INTEGRATION
Decisions made early in development cascade across subsequent stages, often creating downstream constraints that are difficult to reverse. Maintaining an integrated development perspective preserves decision coherence and prevents misalignment that can introduce cumulative scientific and regulatory risk.
WORLDWIDE REGULATORY INSIGHT
Regulatory systems across major markets impose region-specific constraints that shape development strategy. Experience navigating regulatory frameworks across jurisdictions allows these constraints to be anticipated early and incorporated into development planning, preserving decision coherence as programs progress internationally.
SCIENCE
Science that defines boundaries. Insight that expands them.
PRODRUGS &
PRECURSORS
HIGH-SCRUTINY
NEUROACTIVE
MOLECULES
FIRST-IN-CLASS NEUROTHERAPEUTICS
BIOLOGICALLY
DERIVED COMPOUNDS
NON-HALLUCINOGENIC
ANALOGS
BIOSYNTHETIC
MOLECULES
PSYCHEDELIC-DERIVED
COMPOUNDS
EXTRACT-DERIVED COMPOUNDS
COMPLEX NATURAL PRODUCTS
These categories represent development contexts where scientific complexity, regulatory structure, and feasibility constraints converge. Programs in these spaces rarely fit standard development playbooks and require integrated scientific and regulatory strategy.
GLOBAL EXPERIENCE
Regulatory expertise across agencies, regions, and emerging markets.
Drug development operates across multiple regulatory environments. Differences between regulatory systems influence manufacturing strategy, clinical design, and regulatory pathways from the earliest stages of development.
_edited.png)
Experience working across jurisdictions allows these constraints to be anticipated and incorporated into development planning, preserving coherent decision-making as programs progress internationally.
SERVICES
Shaping strategy, guiding development, advancing complex programs.
REGULATORY STRATEGY &
AUTHORITY ENGAGEMENT
Strategic regulatory planning and authority engagement for programs operating under jurisdictional constraints, development risk, and high-scrutiny conditions.
-
Regulatory strategy for authority interactions across major markets
-
Meeting design and regulatory engagement architecture (FDA INTERACT, pre-IND, CTA, formal consultations)
-
Briefing packages and decision-critical regulatory materials
-
Cross-jurisdiction regulatory positioning and constraint analysis
-
High-scrutiny and controlled substance regulatory strategy
MOLECULE, PROCESS, &
TRANSLATIONAL DEVELOPMENT
Scientific and development strategy for molecules where chemical, material, and feasibility constraints shape downstream viability.
-
Route selection and synthetic feasibility analysis
-
Purification strategy, solid-form and salt optimization
-
Resolution of development-critical physicochemical constraints
-
Extract-derived compound refinement and API transitions
-
Technical problem solving at the molecule and process level
SCIENTIFIC DUE DILIGENCE &
DECISION SUPPORT
Independent evaluation for decisions where scientific, technical, regulatory, or classification uncertainty carries material consequences.
-
Independent scientific and technical risk evaluation
-
Development feasibility and constraint analysis
-
Data, claims, and assumption stress testing
-
Decision-critical scientific assessment and interpretation
-
Controlled substance, Federal Analog Act, and regulatory classification assessments
-
Expert opinion development and defensibility support
ADDITIONAL AREAS OF ENGAGEMENT
SCIENTIFIC & REGULATORY
PROGRAM POSITIONING
Strategic framing for programs where scientific rationale, regulatory structure, and evidentiary constraints must remain coherent.
-
Mechanism and development rationale structuring
-
Regulatory-sensitive scientific positioning
-
Evidence, uncertainty, and risk alignment
-
Technical and regulatory narratives for agencies and stakeholders
FRACTIONAL SCIENTIFIC &
DEVELOPMENT LEADERSHIP
Embedded scientific and strategic leadership ensuring continuity of judgment across discovery, preclinical, CMC, manufacturing, and clinical domains under evolving constraints.
-
Interim scientific and development leadership
-
Cross-functional decision architecture and oversight
-
Strategy continuity across discovery, development, and manufacturing
-
Stabilization of programs and technical initiatives under uncertainty
-
Direct involvement in development-critical technical and scientific decisions
WHEN TO ENGAGE
Complex science. Critical development moments.
EARLY MOLECULE EVALUATION
A promising compound exists, but development feasibility, positioning, or regulatory considerations remain unclear.
DEVELOPMENT STRATEGY FORMATION
A program is advancing, but the development pathway across chemistry, preclinical development, regulatory strategy, and clinical planning remains undefined.
REGULATORY PATHWAY PLANNING
A program is approaching regulatory engagement, but the optimal pathway for agency interactions and development strategy remains uncertain.
CHEMISTRY OR MANUFACTURING CHALLENGES
A molecule shows promise, but synthetic routes, process chemistry, scale-up feasibility, or formulation strategy present unresolved challenges.
DISCOVERY-TO-DEVELOPMENT TRANSITION
Discovery-stage findings are compelling, but translating them into a viable development program requires integrated scientific and regulatory planning.
NOVEL OR COMPLEX MOLECULAR PROGRAMS
A therapeutic concept shows promise, but the program falls outside standard development playbooks.
OUR MODEL
Principal-led. Network-supported. Accountable by design.
DIRECT PRINCIPAL ENGAGEMENT
Client engagements are led directly by Melissa Dawn, Principal Scientist and Managing Director. Strategic direction, critical decisions, and client communication remain centralized from kickoff through delivery.
SPECIALIST NETWORK
Specialist expertise is drawn upon when specific technical depth is required, expanding capability while preserving centralized judgment, accountability, and continuity of decision-making.
STRATEGIC INVOLVEMENT
Hands-on involvement is maintained where it materially reduces risk or accelerates clarity, spanning critical development decisions, technical problem solving, and regulatory oversight.
Complex development programs require continuity of judgment, particularly where early decisions shape downstream scientific and regulatory risk.
VALUES
Grounded in science. Focused on people. Committed to integrity.
HUMAN-CENTERED SCIENCE
Scientific progress matters only if it improves real-world outcomes. Every solution is grounded in practical context and designed to deliver meaningful impact.
GLOBAL RESPONSIBILITY
Drug development operates across diverse regulatory systems, cultures, and communities. Work should reflect awareness of how decisions affect the environments in which innovation occurs.
OPERATIONAL INTEGRITY
Scientific and regulatory work demands rigor, clarity, and accountability. Trust is earned through disciplined thinking, transparent communication, and decisions that withstand scrutiny.
